Developments and opportunities in continuous biopharmaceutical manufacturing

Today's biologics manufacturing practices incur high costs to the drug makers, which can contribute to high prices for patients. Timely investment in the development and implementation of continuous biomanufacturing can increase the production of consistent-quality drugs at a lower cost and a f...

Full description

Saved in:
Bibliographic Details
Published in:mAbs 2021-01, Vol.13 (1), p.1903664
Main Authors: Khanal, Ohnmar, Lenhoff, Abraham M.
Format: Article
Language:English
Subjects:
Biological Products - economics
Biopharmaceuticals
bioprocessing
Biosimilar Pharmaceuticals - economics
biosimilars
Biotechnology - economics
chromatography
continuous manufacturing
Cost-Benefit Analysis
Drug Costs
Drug Industry - economics
filtration
Humans
monoclonal antibodies
perfusion culture
process analytical technology
Review
Technology, Pharmaceutical - economics
Time Factors
viral inactivation
Workflow
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Today's biologics manufacturing practices incur high costs to the drug makers, which can contribute to high prices for patients. Timely investment in the development and implementation of continuous biomanufacturing can increase the production of consistent-quality drugs at a lower cost and a faster pace, to meet growing demand. Efficient use of equipment, manufacturing footprint, and labor also offer the potential to improve drug accessibility. Although technological efforts enabling continuous biomanufacturing have commenced, challenges remain in the integration, monitoring, and control of traditionally segmented unit operations. Here, we discuss recent developments supporting the implementation of continuous biomanufacturing, along with their benefits.
ISSN:1942-0862
1942-0870
1942-0870
DOI:10.1080/19420862.2021.1903664